{"entity":{"id":"nct07589257","kind":"trial","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","aka":[],"tldr":"A phase 2 trial of VRT106 for injection in glioma & glioblastoma and diffuse midline glioma, H3 K27-altered, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma is a phase 2 interventional study registered as NCT07589257 by Guangzhou Virotech Pharmaceutical Co., Ltd., with 10 participants planned, started 2026-05-07 and due to reach its primary completion in 2028-06-30. Interventions recorded: VRT106 for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07589257","url":"https://clinicaltrials.gov/study/NCT07589257"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma","dipg-dmg"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07589257","phase":"2","setting":"A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Including Diffuse Intrinsic Pontine Glioma","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","enrolled":10,"outcomes":[]},"route":"/trials/nct07589257/","neighbours":{"cancer":[{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}